Compugen Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Compugen's earnings are forecast to decline at 22.2% per annum while its annual revenue is expected to grow at 10.8% per year. EPS is expected to decline by 2% per annum.
Wichtige Informationen
-22.2%
Wachstumsrate der Gewinne
-2.0%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 27.1% |
| Wachstumsrate der Einnahmen | 10.8% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 14 Aug 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
Aug 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
May 22Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
May 01Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Compugen gains on takeover speculation after iTeos Therapeutics deal
Jun 14Compugen reports updated COM701 data from Phase 1 study at ASCO21
Jun 08Compugen's COM902 demonstrates potential benefit in cancer
Apr 27Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
Feb 08
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)
Jan 04Compugen earns $2M milestone under antibody development deal with AstraZeneca
Dec 23Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 30Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Compugen: Speculative Play For Immuno-Oncology Exposure
Nov 07Compugen Q3 Earnings Preview
Nov 04Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 39 | -15 | 15 | -28 | 2 |
| 12/31/2025 | 43 | -2 | 2 | -14 | 2 |
| 12/31/2024 | 43 | -2 | 66 | 43 | 2 |
| 6/30/2024 | 43 | -10 | 22 | 22 | N/A |
| 3/31/2024 | 36 | -17 | N/A | N/A | N/A |
| 12/31/2023 | 33 | -19 | -36 | -36 | N/A |
| 9/30/2023 | 8 | -32 | N/A | N/A | N/A |
| 6/30/2023 | 8 | -33 | -32 | -32 | N/A |
| 3/31/2023 | 8 | -33 | N/A | N/A | N/A |
| 12/31/2022 | 8 | -34 | -35 | -34 | N/A |
| 9/30/2022 | N/A | -39 | N/A | N/A | N/A |
| 6/30/2022 | 6 | -34 | -30 | -30 | N/A |
| 3/31/2022 | 6 | -34 | N/A | N/A | N/A |
| 12/31/2021 | 6 | -34 | -23 | -23 | N/A |
| 9/30/2021 | 8 | -34 | N/A | N/A | N/A |
| 6/30/2021 | 2 | -36 | -31 | -30 | N/A |
| 3/31/2021 | 2 | -32 | N/A | N/A | N/A |
| 12/31/2020 | 2 | -30 | -28 | -28 | N/A |
| 9/30/2020 | N/A | -28 | N/A | N/A | N/A |
| 6/30/2020 | N/A | -26 | -23 | -23 | N/A |
| 3/31/2020 | N/A | -26 | N/A | N/A | N/A |
| 12/31/2019 | N/A | -27 | -28 | -28 | N/A |
| 9/30/2019 | N/A | -30 | N/A | N/A | N/A |
| 6/30/2019 | 8 | -27 | -22 | -22 | N/A |
| 3/31/2019 | 8 | -31 | N/A | N/A | N/A |
| 12/31/2018 | 18 | -23 | -13 | -13 | N/A |
| 9/30/2018 | 18 | -23 | N/A | N/A | N/A |
| 6/30/2018 | 10 | -29 | -24 | -23 | N/A |
| 3/31/2018 | 10 | -28 | N/A | N/A | N/A |
| 12/31/2017 | N/A | -37 | N/A | -31 | N/A |
| 9/30/2017 | 0 | -36 | N/A | N/A | N/A |
| 6/30/2017 | 0 | -34 | N/A | -27 | N/A |
| 3/31/2017 | 1 | -32 | N/A | N/A | N/A |
| 12/31/2016 | 1 | -32 | N/A | -20 | N/A |
| 9/30/2016 | 9 | -23 | N/A | N/A | N/A |
| 6/30/2016 | 9 | -22 | N/A | -20 | N/A |
| 3/31/2016 | 9 | -23 | N/A | N/A | N/A |
| 12/31/2015 | 9 | -20 | N/A | -26 | N/A |
| 9/30/2015 | 8 | -21 | N/A | N/A | N/A |
| 6/30/2015 | 9 | -20 | N/A | -17 | N/A |
| 3/31/2015 | 11 | -15 | N/A | N/A | N/A |
| 12/31/2014 | 12 | -11 | N/A | -11 | N/A |
| 9/30/2014 | 8 | -13 | N/A | N/A | N/A |
| 6/30/2014 | 7 | -12 | N/A | -7 | N/A |
| 3/31/2014 | 6 | -13 | N/A | N/A | N/A |
| 12/31/2013 | 4 | -14 | N/A | -6 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CGEN is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: CGEN is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: CGEN is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: CGEN's revenue (10.8% per year) is forecast to grow faster than the US market (8.9% per year).
Hohe Wachstumseinnahmen: CGEN's revenue (10.8% per year) is forecast to grow slower than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if CGEN's Return on Equity is forecast to be high in 3 years time